Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.
|Journal||The Pediatric Infectious Disease Journal|
|Early online date||22 Jun 2020|
|Publication status||Early online date - 22 Jun 2020|